105 related articles for article (PubMed ID: 7534858)
1. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS
Lancet; 1995 Apr; 345(8953):820-4. PubMed ID: 7534858
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
[TBL] [Abstract][Full Text] [Related]
3. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
Kamkamidze G; Sullivan T; Charbonneau T
J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
[TBL] [Abstract][Full Text] [Related]
6. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
[TBL] [Abstract][Full Text] [Related]
7. Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.
Leriche-Guérin K; Trabaud MA; Cotte L; Bissuel F; Deruelle E; Rougier P; Trépo C
Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):660-8. PubMed ID: 9352259
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
[TBL] [Abstract][Full Text] [Related]
9. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
[TBL] [Abstract][Full Text] [Related]
10. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
11. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
12. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
14. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
15. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
Carr A; Vella S; de Jong MD; Sorice F; Imrie A; Boucher CA; Cooper DA
AIDS; 1996 Jun; 10(6):635-41. PubMed ID: 8780818
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
